Cargando…

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain

Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods....

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández, Ángel Alonso, Moreso, Francesc, Bayés, Beatriz, Lauzurica, Ricardo, Sánz-Guajardo, Dámaso, Gómez-Huertas, Ernesto, Pereira, Porfirio, Paul, Javier, Crespo, Josep, Amenábar, Juan J., Oliver, Juan, Serón, Daniel
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875045/
https://www.ncbi.nlm.nih.gov/pubmed/20508862
http://dx.doi.org/10.1093/ndtplus/sfq068
_version_ 1782181543722090496
author Hernández, Ángel Alonso
Moreso, Francesc
Bayés, Beatriz
Lauzurica, Ricardo
Sánz-Guajardo, Dámaso
Gómez-Huertas, Ernesto
Pereira, Porfirio
Paul, Javier
Crespo, Josep
Amenábar, Juan J.
Oliver, Juan
Serón, Daniel
author_facet Hernández, Ángel Alonso
Moreso, Francesc
Bayés, Beatriz
Lauzurica, Ricardo
Sánz-Guajardo, Dámaso
Gómez-Huertas, Ernesto
Pereira, Porfirio
Paul, Javier
Crespo, Josep
Amenábar, Juan J.
Oliver, Juan
Serón, Daniel
author_sort Hernández, Ángel Alonso
collection PubMed
description Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (≥18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included. Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17–0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different. Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort.
format Text
id pubmed-2875045
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-28750452010-06-01 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain Hernández, Ángel Alonso Moreso, Francesc Bayés, Beatriz Lauzurica, Ricardo Sánz-Guajardo, Dámaso Gómez-Huertas, Ernesto Pereira, Porfirio Paul, Javier Crespo, Josep Amenábar, Juan J. Oliver, Juan Serón, Daniel NDT Plus Original Article Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (≥18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included. Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17–0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different. Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort. Oxford University Press 2010-06 /pmc/articles/PMC2875045/ /pubmed/20508862 http://dx.doi.org/10.1093/ndtplus/sfq068 Text en © The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hernández, Ángel Alonso
Moreso, Francesc
Bayés, Beatriz
Lauzurica, Ricardo
Sánz-Guajardo, Dámaso
Gómez-Huertas, Ernesto
Pereira, Porfirio
Paul, Javier
Crespo, Josep
Amenábar, Juan J.
Oliver, Juan
Serón, Daniel
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
title Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
title_full Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
title_fullStr Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
title_full_unstemmed Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
title_short Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
title_sort angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in spain
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875045/
https://www.ncbi.nlm.nih.gov/pubmed/20508862
http://dx.doi.org/10.1093/ndtplus/sfq068
work_keys_str_mv AT hernandezangelalonso angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT moresofrancesc angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT bayesbeatriz angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT lauzuricaricardo angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT sanzguajardodamaso angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT gomezhuertasernesto angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT pereiraporfirio angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT pauljavier angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT crespojosep angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT amenabarjuanj angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT oliverjuan angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain
AT serondaniel angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinrenaltransplantationbetween1990and2002inspain